#United States #Johnson & Johnson #Prostate Cancer #Raritan, NJ #pasritamig

New Hope in Prostate Cancer Treatment with Pasritamig

Johnson & Johnson has revealed promising early results from its Phase 1b study on pasritamig (JNJ-78278343), a groundbreaking bispecific T-cell engaging antibody that targets advanced prostate cancer. This investigational therapy combined with the chemotherapy docetaxel has demonstrated a favorable safety profile and significant antitumor activity.

The study was conducted with patients suffering from metastatic castration-resistant prostate cancer (mCRPC), a particularly aggressive form of prostate cancer. Participants had previously undergone treatments that had failed, making the need for effective alternatives even more crucial. The findings documented during the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium underline the potential of this innovative treatment to change outcomes for many patients.

Efficacy and Safety Profile

The results showed that administering pasritamig alongside docetaxel did not introduce any new safety concerns compared to docetaxel alone. The treatment regimen led to notable declines in prostate-specific antigen (PSA) levels, a key marker in assessing prostate cancer progression, with dramatic reductions observed in a significant proportion of participants. This indicates not only tumor shrinkage but also the potential for sustained responses, a critical factor in successfully managing mCRPC.

During the study, 64.7% of patients experienced PSA reductions of 50% or more, while 39.2% achieved reductions of 90% or greater. Notably, taxane-naïve patients, or those who had not undergone previous treatments with taxanes, showed even more impressive results: 75% achieved a decrease of 50% or more, and 53.6% reached reductions of 90%.

A New Mechanism

Pasritamig works through a novel mechanism that recruits and directs T cells - a crucial component of the immune system - toward cancer cells that express human kallikrein 2 (KLK2). The design aims to enhance immune responses specifically against prostate cancer cells while minimizing collateral damage to healthy tissues. This targeted approach may allow for outpatient administration of pasritamig, making it more accessible to patients.

“Encouraging clinical activity alongside a favorable safety profile reinforces the potential of this approach,” said Professor Shahneen Sandhu, a key investigator in the study and medical oncologist at Peter MacCallum Cancer Centre. The collaboration of pasritamig and docetaxel represents a significant advancement in tackling a disease that has shown poor outcomes historically.

Future Prospects

With the promising results of Phase 1b, Johnson & Johnson is preparing for Phase 3 trials, which will further assess pasritamig's efficacy and safety. One ongoing study, KLK2-comPAS, evaluates pasritamig as a standalone treatment, while KLK2-PASenger examines its effectiveness in conjunction with docetaxel. Both studies aim to provide more clarity on the future role of pasritamig in the treatment landscape for mCRPC.

As of now, pasritamig has received Breakthrough Therapy Designation in China and Fast Track designation from the U.S. FDA, underscoring its potential as a valuable therapeutic option. This commitment to innovation is emblematic of Johnson & Johnson’s broader dedication to improving healthcare outcomes through targeted treatment strategies.

In conclusion, the potential of pasritamig to significantly affect the trajectory of prostate cancer treatment represents a ray of hope for patients and families grappling with the challenges posed by metastatic cancer. The future clinical trials will be crucial in determining the role of pasritamig in the ongoing fight against this challenging disease.